
Opinion|Videos|December 21, 2023
Case Presentation: A 73-Year-Old Man with Myelofibrosis (MF)
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, presents the case of a 73-year-old man with myelofibrosis.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5








































